74 related articles for article (PubMed ID: 18497509)
1. Small molecule inhibitors of tyrosine kinase: waiting for the good news in colorectal cancer as well.
Sobrero A; Andretta V
Onkologie; 2008 May; 31(5):224-5. PubMed ID: 18497509
[No Abstract] [Full Text] [Related]
2. Opportunities and challenges in the development of kinase inhibitor therapy for cancer.
Sawyers CL
Genes Dev; 2003 Dec; 17(24):2998-3010. PubMed ID: 14701871
[No Abstract] [Full Text] [Related]
3. The era of targeted therapies: increasing role for novel oncologic drugs in dermatology.
Montella L; Palmieri G; Lacouture M
Arch Dermatol; 2007 Jun; 143(6):788-9. PubMed ID: 17576948
[No Abstract] [Full Text] [Related]
4. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
Eck MJ; Manley PW
Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
[TBL] [Abstract][Full Text] [Related]
5. [Kinase inhibitors].
Hagiwara M; Usuki H
Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1708-12. PubMed ID: 18051404
[No Abstract] [Full Text] [Related]
6. Small molecule tyrosine kinase inhibitor and depression.
Quek R; Morgan JA; George S; Butrynski JE; Polson K; Meyer F; Demetri GD; Block SD
J Clin Oncol; 2009 Jan; 27(2):312-3. PubMed ID: 19064960
[No Abstract] [Full Text] [Related]
7. An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola.
Moore WJ; Richard D; Thorarensen A
Expert Opin Ther Pat; 2010 Dec; 20(12):1703-22. PubMed ID: 21073366
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.
El-Deeb IM; Park BS; Jung SJ; Yoo KH; Oh CH; Cho SJ; Han DK; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Oct; 19(19):5622-6. PubMed ID: 19700314
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
[TBL] [Abstract][Full Text] [Related]
11. [Statins and colorectal cancer prevention].
von Delius S
Z Gastroenterol; 2006 Jun; 44(6):543-4. PubMed ID: 16773521
[No Abstract] [Full Text] [Related]
12. Chronomodulated chemotherapy for colorectal cancer: failing the test of time?
Takimoto CH
Eur J Cancer; 2006 Mar; 42(5):574-81. PubMed ID: 16439112
[No Abstract] [Full Text] [Related]
13. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
Lang A; Graeven U
Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
[No Abstract] [Full Text] [Related]
14. Structural biology contributions to tyrosine kinase drug discovery.
Cowan-Jacob SW; Möbitz H; Fabbro D
Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
[TBL] [Abstract][Full Text] [Related]
15. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
16. What is the right dose? The elusive optimal biologic dose in phase I clinical trials.
Adjei AA
J Clin Oncol; 2006 Sep; 24(25):4054-5. PubMed ID: 16943522
[No Abstract] [Full Text] [Related]
17. Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care.
Keefe D; Anthony L
Curr Opin Support Palliat Care; 2008 Mar; 2(1):19-21. PubMed ID: 18685389
[No Abstract] [Full Text] [Related]
18. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
Beel K; Janssens A; Verhoef G; Vandenberghe P
Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553
[TBL] [Abstract][Full Text] [Related]
19. Surufatinib in neuroendocrine tumours.
Das M
Lancet Oncol; 2019 Apr; 20(4):e196. PubMed ID: 30880071
[No Abstract] [Full Text] [Related]
20. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
[No Abstract] [Full Text] [Related]
[Next] [New Search]
